enGene Holdings Inc.

NASDAQ:ENGN

Biotechnology

Healthcare
$1.85 -1.15%

-$0.02 today

Market cap
$123.98M
Beta
-0.29
P/E (TTM)
-1.8
EPS (TTM)
-$0.95
52W Low $1.40High $12.25

Volume 2.81M

Average 1.58M

ENGN Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

enGene Holdings Inc.NASDAQ: ENGN

Net Receivables · Q2 FY2026 · quarter ended Apr 2026

Net receivables rises 448.2% from a year ago

Net receivables stood at $2.92M at the end of Q2 FY2026, up 448.2% from a year earlier and up 144.1% from the prior quarter.

Context

  • Net receivables amounted to 1.0% of total assets at the end of Q2 FY2026, up 0.8 pp from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +448.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterApr 2026
$2.92M+144.1% QoQ
Last fiscal yearOct 2025
$2.23M+115.8% YoY
Year agoApr 2025
$533K+448.2% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+448.2%——
1 year+115.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
2.23M USD
Year-over-year change
+115.8%

Net Receivables vs competitors

How ENGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +448.2% is the highest of 9, against a peer median of -11.9%.
  • Net receivables amounts to 1.0% of total assets for ENGN, versus a peer median of 0.8%.
ENGN Competitors
Net Receivables for ENGN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AMRNAmarin Corporation plcMar 2026$108.05M USD+1.2%-1.1%16.7%
SLNSilence Therapeutics plcMar 2026$22.22M USD+31.9%+199.6%19.3%
DBVTDBV Technologies S.A.Mar 2026$15.1M USD+22.7%+15.4%5.7%
CLLSCellectis S.A.Mar 2026$15.05M USD-41.0%+12.9%5.2%
ENGNenGene Holdings Inc.Apr 2026$2.92M USD+448.2%—1.0%
ALTAltimmune, Inc.Mar 2026$1.67M USD-32.4%-11.9%0.5%
ACIUAC Immune S.A.Mar 2026CHF 1.51M CHF+63.5%+18.7%1.1%
LRMRLarimar Therapeutics, Inc.Mar 2026$791K USD-25.1%—0.4%
ANROAlto Neuroscience, Inc.Mar 2026$0 USD——0.0%
ANNXAnnexon, Inc.Mar 2026$0 USD——0.0%
KRROKorro Bio, Inc.Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding ENGN) —-11.9%+14.2%0.8%

Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Cash & Equivalents1.07M314.15K81.52M173M50.15M
Short-term Investments0076K65.4M143.66M
Net Receivables002.34M1.03M2.23M
Inventory00000
Other Current Assets001.5M7.93M5.35M
Total Current Assets1.57M511.8K85.44M247.36M201.39M
Property, Plant & Equipment (Net)00589K2.91M10.19M
Goodwill00000
Intangible Assets00000
Long-term Investments129.67M131.53M70K59.53M8.52M
Tax Assets00000
Other Non-current Assets209.05K939K860K1.37M1.36M
Total Non-current Assets129.88M131.53M1.52M63.81M20.08M
Total Assets131.45M132.04M86.96M311.17M221.47M
Account Payables001.16M1.41M6.69M
Short-term Debt1.05M1.27M562K1.12M10.02M
Tax Payables022K39K00
Deferred Revenue00000
Other Current Liabilities327.45K893.51K2.69M8.65M11.2M
Total Current Liabilities327.45K893.51K5.26M14.66M31.98M
Long-term Debt009.22M22.47M15.32M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)3.73M0000
Other Non-current Liabilities03.73M000
Total Non-current Liabilities3.73M3.73M9.22M23.9M21.78M
Total Liabilities4.05M4.62M14.47M38.56M53.76M
Common Stock129.67M131.53M259.37M509.81M513.28M
Retained Earnings(2.28M)(4.11M)(199.59M)(254.73M)(372.03M)
Accumulated OCI00(1.02M)(1.42M)(888K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity127.39M127.42M72.49M272.61M167.71M
Total Debt4.16M32.11M9.78M25.02M31.8M
Net Debt(1.07M)(314.15K)(71.74M)(147.98M)(18.36M)

enGene Holdings Inc.

NASDAQ:ENGN

Intrinsic Alpha fair value

Locked

Current Price

$1.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.